SCHEDULE: Coherus Oncology Shareholder Filing

Timothy G. Youngquist 2020 Irrevocable Trust reports 8.3% stake in Coherus Oncology, Inc. as of March 31, 2026.

Summary

• The Timothy G. Youngquist 2020 Irrevocable Trust has filed a Schedule 13G, indicating beneficial ownership of 12,750,800 shares of Coherus Oncology, Inc. common stock.
• This represents 8.3% of the company's outstanding common stock as of April 16, 2026.
• The filing is an amendment to correct information from a previous filing.
• The Trust holds sole voting and dispositive power over these shares.
• The filing also notes the inclusion of 460,000 shares underlying call options exercisable within 60 days.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily reports existing ownership and corrects previous information without new strategic announcements or financial performance data.

Positives

• The Timothy G. Youngquist 2020 Irrevocable Trust maintains a significant ownership stake of 8.3% in Coherus Oncology, Inc.
• The Trust has sole voting and dispositive power, indicating clear control over its holdings.

Risks

• The filing mentions 460,000 shares of common stock underlying call options that constitute a right to acquire shares within 60 days, which could lead to increased dilution if exercised.

Future Outlook

The filing does not contain forward-looking statements or guidance regarding future performance.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are typically made by institutional investors or significant shareholders who acquire more than 5% of a company's stock. This filing indicates a substantial passive investment in Coherus Oncology, Inc.

Stakeholder Impact

• Shareholders: The filing confirms a significant passive ownership stake, which could be viewed positively by some investors as a sign of confidence in the company's long-term prospects. However, it does not indicate any active involvement in management or strategy.
• Management: The filing does not directly impact management, but it confirms the level of institutional interest in the company.

Key Dates

Keywords

Coherus Oncology, Schedule 13G, Timothy G. Youngquist 2020 Irrevocable Trust, Beneficial Ownership, Common Stock, Shareholder Filing, SEC Filing